^
Association details:
| Biomarker: | NRAS mutation |
|---|---|
| Cancer: | Melanoma |
| Drug: | Tecentriq (atezolizumab) (PD-L1 inhibitor) + belvarafenib (RG6185) (pan-RAF inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Belvarafenib penetrates the BBB and shows potent antitumor activity in a murine melanoma brain metastasis model
Published date:
02/10/2023
Excerpt:
Belvarafenib strongly suppressed melanoma in BRAF V600E mutant A375SM tumor-bearing mice. It also significantly inhibited tumor growth in NRAS mutant SK-MEL-30 and K1735 tumor-bearing mice and synergized to enhance the antitumor activity combined with cobimetinib or atezolizumab.
DOI:
10.1007/s10585-023-10198-7
